search
Back to results

Effectiveness of a Digital Therapeutic on Type 2 Diabetes

Primary Purpose

Type2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
FareWell Program
Sponsored by
FareWell
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type2 Diabetes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • diagnosis of type 2 diabetes

Exclusion Criteria:

  • Inability to understand, consent to, or comply with the study protocol for any reason, including inability to read or comprehend English.
  • Does not have a smartphone (either an iPhone or Android phone)

Sites / Locations

  • FareWell LLC

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

FareWell Program

Arm Description

All participants receive the FareWell Program intervention in this evaluation study

Outcomes

Primary Outcome Measures

Level of engagement with the assigned mobile app
How do participants interact with the digital program (e.g. feature use, coaching calls completed, targets tracked, targets met)

Secondary Outcome Measures

Change in self-reported Hemoglobin A1c
Comparison of baseline and end program self reported Hemoglobin A1c
Change in self-reported diabetes medication type or dose
Comparison of diabetes medications reported at baseline to any changes reported at the end of the study or mid-study

Full Information

First Posted
December 6, 2017
Last Updated
August 19, 2019
Sponsor
FareWell
search

1. Study Identification

Unique Protocol Identification Number
NCT03369626
Brief Title
Effectiveness of a Digital Therapeutic on Type 2 Diabetes
Official Title
Effectiveness of a Digital Therapeutic in a Geographically Distributed Population With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
July 26, 2017 (Actual)
Primary Completion Date
January 31, 2018 (Actual)
Study Completion Date
February 28, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
FareWell

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A clinical study evaluating a three month digitally delivered lifestyle change program in adults with Type 2 Diabetes. The FareWell Program (the "Program") aims to reduce well-established biomarkers of cardiometabolic diseases, weight, and medications. The current study is designed to evaluate to what degree adults with Type 2 Diabetes engaged with the Program can improve glycemic control and/or decrease medication needs.
Detailed Description
The Program aims to reduce well-established biomarkers of cardiometabolic diseases, weight, and medications. It includes meal planning tools, smart shopping lists, recipes curated by a physician, dietitian and chef educator, daily self-monitoring features with personalized weekly goals, bi-weekly live one-on-one health coaching and support from an online member community, and an educational curriculum. Subjects in the Program may receive support from other members of a Care Team (lifestyle medicine physician, chef educator, registered dietitian and/or psychologist/psychiatrist) as needed. The Care Team does not provide medical advice, nor replace traditional medical care. Instead, the Care Team encourages behavior change by providing support and sharing its expertise. Study participants will have access to the Program for a twelve week period and will be asked to complete short health surveys at baseline and at the end of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
evaluation of pre/post measures of a single group
Masking
None (Open Label)
Allocation
N/A
Enrollment
118 (Actual)

8. Arms, Groups, and Interventions

Arm Title
FareWell Program
Arm Type
Other
Arm Description
All participants receive the FareWell Program intervention in this evaluation study
Intervention Type
Behavioral
Intervention Name(s)
FareWell Program
Intervention Description
The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.
Primary Outcome Measure Information:
Title
Level of engagement with the assigned mobile app
Description
How do participants interact with the digital program (e.g. feature use, coaching calls completed, targets tracked, targets met)
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Change in self-reported Hemoglobin A1c
Description
Comparison of baseline and end program self reported Hemoglobin A1c
Time Frame
12 weeks
Title
Change in self-reported diabetes medication type or dose
Description
Comparison of diabetes medications reported at baseline to any changes reported at the end of the study or mid-study
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: diagnosis of type 2 diabetes Exclusion Criteria: Inability to understand, consent to, or comply with the study protocol for any reason, including inability to read or comprehend English. Does not have a smartphone (either an iPhone or Android phone)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Berman, MD
Organizational Affiliation
FareWell
Official's Role
Principal Investigator
Facility Information:
Facility Name
FareWell LLC
City
San Francisco
State/Province
California
ZIP/Postal Code
94108
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Effectiveness of a Digital Therapeutic on Type 2 Diabetes

We'll reach out to this number within 24 hrs